基本信息
- 标准SMILES
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O- InChIKey
CTPOHARTNNSRSR-APJZLKAGSA-N- 分子式
- C24H30O5
- 平均分子量
- 398.5 g/mol
- 单同位素质量
- 398.20932406
概述
Beraprost is an organic heterotricyclic compound that is (3aS,8bS)-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan in which the hydrogens at positions 1R, 2R and 5 are replaced by (3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl, hydroxy and 3-carboxypropyl groups, respectively. It is a prostaglandin receptor agonist which is approved to treat pulmonary arterial hypertension in Asia. It has a role as a vasodilator agent, an antihypertensive agent, a platelet aggregation inhibitor, a prostaglandin receptor agonist and an anti-inflammatory agent. It is a secondary allylic alcohol, a monocarboxylic acid, an organic heterotricyclic compound, a secondary alcohol and an enyne. It is a conjugate acid of a beraprost(1-).
名称与标识
- 首选名称
- Beraprost
- IUPAC
- 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
名称与别名
beraprostBeraprostum88430-50-6MDL-201229ML-1229MDL 201229ML 122935E3NJJ4O6TRK-100STP FREE ACIDDTXSID7049136CHEBI:1356331H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-
展开更多名称
2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic acid4-(1,2,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrateRefChem:119032DTXCID4029062B01AC194-(4-hydroxy-3-((1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-7-oxatricyclo(6.4.0.0^(2,6))dodeca-1(12),8,10-trien-9-yl)butanoic acidsodium 4-((2S,3R,4R,6S)-4-hydroxy-3-((1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-7-oxatricyclo(6.4.0.02,?)dodeca-1(12),8,10-trien-9-yl)butanoate218432-32-7
数据库标识
- CAS
88430-50-6- PubChem CID
- 6917951
- DTXSID
DTXSID7049136- ChEMBL
CHEMBL1207745- ChEBI
CHEBI:135633- UNII
- 35E3NJJ4O6
- Nikkaji
- J372.792K
性质
结构计算性质
- XLogP
- 3.2
- 极性表面积
- 87 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 可旋转键
- 8
- 重原子
- 29
- 形式电荷
- 0
- 复杂度
- 659
实验与物化性质
Endocrine DisruptorsPotential endocrine disrupting compound
安全与法规
毒理信息
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Beraprost
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
化学与工业
药理信息
ATC Code
B - Blood and blood forming organs
QB - Blood and blood forming organs
QC - Cardiovascular system
Pharmacodynamics
Beraprost is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. Comparative data from a large randomised trial indicated that the drug appears as effective as ticlopidine in patients with these conditions. In patients with intermittent claudication, significant benefits of beraprost compared with placebo were reported in a randomised clinical trial; however, the use of beraprost in these patients is not supported by recent preliminary unpublished data from a large, phase III, placebo-controlled study. Limited data suggest some efficacy with long-term beraprost treatment of patients with PAH, where options are few and where oral administration of the drug could be a considerable advantage over intravenous prostacyclin (PGI2) therapy.
Mechanism of Action
Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca<sup>2+</sup> from intracellular storage sites. This reduction in the influx of Ca<sup>2+</sup> has been postulated to cause relaxation of the smooth muscle cells and vasodilation.
Biological Half-Life35–40 minutes
MeSH Pharmacological Classification
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Drugs used to cause dilation of the blood vessels.
Absorption, Distribution and ExcretionOral bioavailability is 50–70%.
相关反应
1 条
关联笔记
加载中…